

Zafamax Capsule

250mg

Azithromycin Capsules USP

When you are
Caught in
Bacterial Infection

Zafamax (Azithromycin) is a broad-spectrum macrolide antibiotic with a long half-life and excellent tissue penetration. *Aust Prescr. 2015 Jun; 38(3): 87-89.*

INDICATIONS

- **Zafamax** is effective in URTI including Otitis Media, Pharyngitis/Tonsillitis & Sinusitis ⁽¹⁾
- **Zafamax** is effective in LRTI including Bronchitis and Pneumonia ⁽²⁾
- **Zafamax** is effective in Sexually Transmitted Diseases in Men and Women ⁽³⁾
- **Zafamax** is effective in Skin & Soft Tissue Infections ⁽⁵⁾

DOSAGE & ADMINISTRATION

Acute bacterial sinusitis	10 mg/kg once daily for 3 days ⁽⁴⁾
Community-acquired pneumonia	10 mg/kg as a single dose on Day 1 followed by 5 mg/kg once daily on Days 2 through ⁽⁴⁾
Acute bacterial exacerbation of chronic bronchitis (mild to moderate)	500mg as a single dose on Day 1, followed by 250mg once daily on Days 2 through 5 or 500 mg once daily for 3 days. Acute bacterial sinusitis 500 mg once daily for 3 days. ⁽⁴⁾
Chlamydia Infection	1gm of orally in a single dose ⁽⁴⁾

PRESCRIBING INFORMATION:

COMPOSITION: Each 250mg capsule contains: Azithromycin USP 250mg.

INDICATIONS: Azithromycin is indicated for infections caused by susceptible organisms; In lower respiratory tract infections including bronchitis and pneumonia, In upper respiratory tract infections including otitis media, pharyngitis/tonsillitis and sinusitis, skin and soft tissue infections and acne, mild to moderate typhoid fever caused by multi-drug resistant strains. In sexually transmitted diseases in men and women, azithromycin is indicated in the treatment of uncomplicated genital infections due to Chlamydia trachomatis. Azithromycin is indicated as second line therapy for typhoid fever caused by s.typhi and s.paratyphi. **DOSAGE AND ADMINISTRATION:** Azithromycin should be administered as single dose, and as common with many other antibiotics, should be taken at least 1 hour before or 2 hours after food. **Adults:** For respiratory tract infections and skin and soft tissue infections the total dose is 1.5g which should be given as 500mg as a single dose daily for 3 days. Alternatively an initial dose of 500mg in the first day may be followed by 250mg daily for further 4 days. For sexually transmitted diseases caused by Chlamydia trachomatis the dose is 1g given as a single dose. For typhoid fever, the dose is 500mg to 1000mg once daily for 5-7 days. **Use in children:** There is no information on children under six months of age. The dose in children is 10mg/kg as a single daily dose for 3 days. For typhoid fever therapy should be given for 7 days. **CONTRA-INDICATIONS:** Azithromycin is contra-Indicated In patients with a known hypersensitivity to azithromycin or any macrolide antibiotics. **PRECAUTIONS AND WARNINGS:** As with any antibiotic, observation for signs of super infection with non susceptible organisms, including fungi is recommended. As with erythromycin and other macrolides, serious allergic reactions, including angioneurotic oedema and anaphylaxis have been reported. Some of these reactions with azithromycin have resulted in recurrent symptoms and required a long period of observation and treatment. **USE IN RENAL IMPAIRMENT:** No dosage adjustment is needed in patients with mild renal impairment (Creatinine Clearance >40 ml/min.) but there are no data regarding azithromycin usage in patients with more severe renal impairment, thus caution should be exercised in using azithromycin in these patients. **OVERDOSAGE:** There is no data on overdosage with azithromycin. Typical symptoms of overdosage with macrolide antibiotics include hearing loss, severe nausea, vomiting and diarrhoea. Gastric lavage and general supportive measures are indicated. **INSTRUCTIONS / STORAGE:** Protect from light and moisture, Do not store above 25°C. Keep all the medicines out of the reach of children. **PRESENTATION:** Zafamax 250mg 6's capsules in a pack.



- Ref: 1 - <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918299/>
 2 - Cochrane Database Syst Rev. 2015 Mar; 2015(3): CD001954
 3 - Am Fam Physician. 1999 Oct 1;60(5):1387-1394
 4 - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017
 5 - Journal of Antimicrobial Chemotherapy, Volume 25, Issue suppl_A, 1990,Pages 115-121

“Medicines For All”



Zafa Pharmaceutical Laboratories (Private) Ltd.

L-1/B, Block-22, FEDERAL 'B' INDUSTRIAL AREA, KARACHI-75950 (PAKISTAN)

Email: zafaph@cyber.net.pk, Website: www.zafa.com.pk

